Bibliographic Details
| Title: |
Conventional and novel [18F]FDG PET/CT features as predictors of CAR-T cell therapy outcome in large B-cell lymphoma. |
| Authors: |
Leithner, Doris, Flynn, Jessica R., Devlin, Sean M., Mauguen, Audrey, Teng Fei, Shang Zeng, Junting Zheng, Imber, Brandon S., Hubbeling, Harper, Mayerhoefer, Marius E., Bedmutha, Akshay, Luttwak, Efrat, Corona, Magdalena, Dahi, Parastoo B., Luna de Abia, Alejandro, Landego, Ivan, Lin, Richard J., Palomba, M. Lia, Scordo, Michael, Park, Jae H. |
| Source: |
Journal of Hematology & Oncology; 4/23/2024, Vol. 17 Issue 1, p1-5, 5p, 2 Graphs |
| Abstract: |
Relapse and toxicity limit the effectiveness of chimeric antigen receptor T-cell (CAR-T) therapy for large B-cell lymphoma (LBCL), yet biomarkers that predict outcomes and toxicity are lacking. We examined radiomic features extracted from pre-CAR-T 18F-fluorodeoxyglucose positron emission tomography/computed tomography ([18F]FDG PET/CT) scans (n=341) of 180 patients (121 male; median age, 66 years). Three conventional (maximum standardized uptake value [SUVmax], metabolic tumor volume [MTV], total lesion glycolysis [TLG]) and 116 novel radiomic features were assessed, along with inflammatory markers, toxicities, and outcomes. At both preapheresis and pre-infusion time points, conventional PET features of disease correlated with elevated inflammatory markers. At pre-infusion, MTV was associated with grade≥2 cytokine release syndrome (odds ratio [OR] for 100 mL increase: 1.08 [95% confidence interval (CI), 1.01–1.20], P=0.031), and SUVmax was associated with failure to achieve complete response (CR) (OR 1.72 [95% CI, 1.24–2.43], P<0.001). Higher pre-apheresis and pre-infusion MTV values were associated with shorter progression-free survival (PFS) (HR for 10-unit increase: 1.11 [95% CI, 1.05–1.17], P<0.001; 1.04 [95% CI, 1.02–1.07], P<0.001) and shorter overall survival (HR for 100-unit increase: 1.14 [95% CI, 1.07–1.21], P<0.001; 1.04 [95% CI, 1.02–1.06], P<0.001). A combined MTV and LDH measure stratified patients into high and low PFS risk groups. Multiple pre-infusion novel radiomic features were associated with CR. These quantitative conventional [18F]FDG PET/CT features obtained before CAR-T cell infusion, which were correlated with inflammation markers, may provide prognostic biomarkers for CAR-T therapy efficacy and toxicity. The use of conventional and novel radiomic features may thus help identify high-risk patients for earlier interventions. [ABSTRACT FROM AUTHOR] |
|
Copyright of Journal of Hematology & Oncology is the property of BioMed Central and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Complementary Index |
